<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03976596</url>
  </required_header>
  <id_info>
    <org_study_id>PBRC 2018-051</org_study_id>
    <nct_id>NCT03976596</nct_id>
  </id_info>
  <brief_title>Measurement of in Vivo Mitochondrial Capacity in Infants</brief_title>
  <official_title>Measurement of in Vivo Mitochondrial Capacity in Infants: a 31P-MRS Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pennington Biomedical Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pennington Biomedical Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching aim of this project is to determine the test re-test reliability of
      31P-magnetic resonance spectroscopy measurements in infants. Primary endpoints include two
      separate measures of in vivo mitochondrial capacity (ATPmax) over a 1-10 day period to assess
      feasibility and reliability.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Study temporarily paused due to COVID-19 and expected to resume. This is not a suspension of
    IRB approval.
  </why_stopped>
  <start_date type="Actual">May 21, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>In vivo mitochondrial capacity (ATPmax)</measure>
    <time_frame>1 day</time_frame>
    <description>In vivo mitochondrial capacity as measured by phosphorus magnetic resonance spectroscopy</description>
  </primary_outcome>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Healthy Infants</condition>
  <eligibility>
    <study_pop>
      <textblock>
        This cross-sectional study will enroll up to 18 infants. Infants will complete 2 study
        visits over a 1-10 day period for outcome measures.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy, full-term infant

          -  aged 14-28 days at Visit 1

          -  willingness of parents to be notified of incidental findings from study procedures

        Exclusion Criteria:

          -  born preterm

          -  implanted metal or electronic objects that render MRI unsafe

          -  unable to complete 2 clinic visits 1-10 days apart at Pennington Biomedical Research
             Center
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>28 Days</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Leanne M Redman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pennington Biomedical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 4, 2019</study_first_submitted>
  <study_first_submitted_qc>June 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pennington Biomedical Research Center</investigator_affiliation>
    <investigator_full_name>Leanne Redman</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>neonates</keyword>
  <keyword>mitochondria</keyword>
  <keyword>MRI</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

